Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Kiora Pharmaceuticals Inc (KPRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: KPRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11
1 Year Target Price $11
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.25% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.83M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 2 | Beta -0.68 | 52 Weeks Range 2.51 - 4.86 | Updated Date 06/29/2025 |
52 Weeks Range 2.51 - 4.86 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.26 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -48421.22% |
Management Effectiveness
Return on Assets (TTM) -15.83% | Return on Equity (TTM) -41.13% |
Valuation
Trailing PE - | Forward PE 2.41 | Enterprise Value -15119642 | Price to Sales(TTM) 441.36 |
Enterprise Value -15119642 | Price to Sales(TTM) 441.36 | ||
Enterprise Value to Revenue 569.41 | Enterprise Value to EBITDA -1.03 | Shares Outstanding 3043860 | Shares Floating 2074267 |
Shares Outstanding 3043860 | Shares Floating 2074267 | ||
Percent Insiders 3.6 | Percent Institutions 45.65 |
Analyst Ratings
Rating 2 | Target Price 11 | Buy 2 | Strong Buy - |
Buy 2 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Kiora Pharmaceuticals Inc
Company Overview
History and Background
Kiora Pharmaceuticals, formerly Ophthalmology Limited, is a biopharmaceutical company focused on developing and commercializing treatments for retinal diseases. It was founded in 2017 and has transitioned through various clinical trial stages.
Core Business Areas
- Retinal Disease Therapeutics: Developing and commercializing therapies for the treatment of various retinal diseases, including inherited retinal diseases and dry age-related macular degeneration (AMD).
Leadership and Structure
The leadership team includes Mark L Baum (CEO), Scott Mavis (CMO) and the organizational structure is typical of a clinical stage biopharmaceutical company with departments for research, clinical development, and regulatory affairs.
Top Products and Market Share
Key Offerings
- KIO-301 (GABA-modulating prosthetic approach): A light-sensitive small molecule being developed to restore light perception in patients with advanced retinal diseases. It is in early stage clinical trials. Market share is currently 0% due to not being commercialized. Competitors include companies developing gene therapies and optogenetic therapies for retinal diseases.
- KIO-101 (DHODH inhibitor): A small molecule that is being developed for back-of-the-eye auto-immune and inflammatory diseases. It is currently in pre-clinical studies. Market share is currently 0% due to not being commercialized. Competitors include companies developing drugs for uveitis and AMD.
Market Dynamics
Industry Overview
The biopharmaceutical industry focused on retinal diseases is rapidly growing, driven by an aging population and advancements in gene therapy, drug delivery systems, and diagnostics.
Positioning
Kiora is positioned as a company developing innovative therapies for inherited retinal diseases and other retinal conditions with unmet medical needs. Its competitive advantage lies in its novel approach to restoring vision and treating inflammatory retinal diseases.
Total Addressable Market (TAM)
The TAM for retinal disease therapeutics is estimated to be in the tens of billions of dollars globally. Kiora is positioned to capture a share of this market through successful clinical development and commercialization of its pipeline.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approaches
- Experienced management team
- Focus on unmet medical needs
- Potential for breakthrough therapies
Weaknesses
- Early stage clinical development
- Limited financial resources
- High risk of clinical trial failure
- Dependence on key personnel
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through acquisitions or licensing
- Positive clinical trial results
- Orphan drug designation and expedited regulatory pathways
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- AGN
- REGN
- ALNY
Competitive Landscape
Kiora faces significant competition from larger, well-established pharmaceutical companies. Its advantages include its novel therapeutic approaches and focus on niche markets. Its disadvantages include limited financial resources and the high risk of clinical trial failure.
Growth Trajectory and Initiatives
Historical Growth: Kiora's historical growth is characterized by progressing through preclinical and early clinical trial stages.
Future Projections: Future growth is contingent upon successful clinical trial outcomes and securing additional funding. Analyst estimates are highly speculative due to the early stage nature of the company's pipeline.
Recent Initiatives: Recent initiatives include the advancement of KIO-301 into clinical trials and the development of KIO-101.
Summary
Kiora Pharmaceuticals is a high-risk, high-reward biopharmaceutical company focused on developing innovative therapies for retinal diseases. Its success is dependent on achieving positive clinical trial outcomes and securing additional funding. The company faces strong competition from established players in the ophthalmology space and the inherent risks associated with drug development, making it a speculative investment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Kiora Pharmaceuticals Inc. Investor Relations
- SEC Filings
- Industry reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The information provided is based on publicly available data and may not be completely accurate or up-to-date. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kiora Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Encinitas, CA, United States | ||
IPO Launch date 2015-07-31 | President, CEO & Director Dr. Brian M. Strem Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | Website https://www.kiorapharma.com |
Full time employees 12 | Website https://www.kiorapharma.com | ||
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.